USE OF APPROVED DRUGS FOR UNLABELED INDICATIONS

被引：0
作者：
不详
机构：
来源：
CLINICAL PEDIATRICS | 1982年 / 21卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
引用
收藏
页码：544 / 544
页数：1
相关论文
共 50 条
[21]   AN ANALYSIS OF REGULATORY REVIEW TIMES OF SUPPLEMENTAL INDICATIONS FOR ALREADY APPROVED DRUGS [J].
DIMASI, JA ;
BROWN, JS ;
LASAGNA, L .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (02) :195-195
[22]   NDA REVIEW TIME FOR NEW INDICATIONS OF ALREADY-APPROVED DRUGS [J].
SPIVEY, RN ;
LASAGNA, L ;
TRIMBLE, AG .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 39 (02) :230-230
[23]   Off-label use of approved drugs [J].
Landow, L .
CHEST, 1999, 116 (03) :589-591
[24]   Use of not yet approved drugs in daily practice [J].
Wollenhaupt, J .
ZEITSCHRIFT FUR RHEUMATOLOGIE, 2001, 60 (06) :450-452
[25]   Off-label use of approved drugs [J].
DeVita, V. T., Jr. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (04) :181-181
[26]   Off-label use of approved drugs [J].
Vincent T. DeVita .
Nature Reviews Clinical Oncology, 2009, 6 :181-181
[27]   INDICATIONS + CONTRAINDICATIONS FOR USE OF CORTICOSTEROID DRUGS [J].
PRINCE, HE .
ANNALS OF ALLERGY, 1964, 22 (08) :399-&
[28]   EFFECTIVE ANTIFUNGAL DRUGS AND INDICATIONS FOR THEIR USE [J].
ROBINSON, HM .
MEDICAL CLINICS OF NORTH AMERICA, 1967, 51 (05) :1181-&
[29]   Drug targeting in Acanthamoeba keratitis: rational of using drugs that are already approved for ocular use in non-keratitis indications [J].
Baig, Abdul Mannan .
EYE, 2019, 33 (03) :509-511
[30]   Drug targeting in Acanthamoeba keratitis: rational of using drugs that are already approved for ocular use in non-keratitis indications [J].
Abdul Mannan Baig .
Eye, 2019, 33 :509-518
12345